ApprovalTrail

Approval · Notice of Compliance 15815 · 2014

TEVA-DUTASTERIDE: Notice of Compliance 15815

Issued July 16, 2014

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
15815
Date
July 16, 2014
Company
Teva Canada LimitedToronto, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
Abbreviated New Drug Submission (ANDS)
Submission class
Other
Therapeutic class
Type i and ii 5 alpha-reductase inhibitor
Canadian reference product
AVODART (Glaxosmithkline Inc)

Products in this notice

BrandDINStatus today
TEVA-DUTASTERIDE02408287Marketed

Medicinal ingredients